, the company announced the completion of the dose escalation phase for Avent AML trial in December of last year.
So we are up to the dose expansion cohort now which is enrolling older / unfit patients with newly diagnosed
As I mentioned in a previous post, Dr Maiti mainly focuses on adverse risk patients in his Zoom presentation. MD Anderson will complete a retrospective randomised trial using other data they have on file for each sub population to determine whether there is clinical benefit for this new triplet therapy. Dr Maiti gave a range in efficacy for standard of care therapy in respect complete responses between 40-60%. The key metric though is the 1 year survival rate which he is hoping to increase from ~40% by another 15-20%.
A few more call outs:
- as at the 31 Mar Qtrly, only 1 patient had been dosed and a second enrolled. This means that at least 2 of the patients and potentially all 3 patients have not completed all their 4 cycles of NK therapy (because this would take at least 4 months per patient).
@Shellbell mentioned in an earlier post that they only received one cycle of NK each! Hoping she can confirm if this been validated by the company;
- The CRi responses can potentially transition to CR responses over time because neutrophil and/or platelet counts gradually recover after the bone marrow achieves remission. CR responses are correlated with improved patient outcomes;
- At this stage, we only have immature data for a very small sample with limited details in respect to the patient characteristics.
Here is the trial protocol for your reference:
(20min delay)